Chimeric foot-and-mouth disease virus serotype O displaying a serotype Asia1 antigenic epitope at the surface
暂无分享,去创建一个
[1] B. Pattnaik,et al. Engineering foot-and-mouth disease virus serotype O IND R2/1975 for one-step purification by immobilized metal affinity chromatography. , 2015, Biologicals : journal of the International Association of Biological Standardization.
[2] R. Kormelink,et al. Feasibility of Cowpea chlorotic mottle virus-like particles as scaffold for epitope presentations , 2015, BMC Biotechnology.
[3] M. Rahman,et al. Antigenic heterogeneity of capsid protein VP1 in foot-and-mouth disease virus (FMDV) serotype Asia 1 , 2013, Advances and applications in bioinformatics and chemistry : AABC.
[4] Decheng Yang,et al. Insertion of type O-conserved neutralizing epitope into the foot-and-mouth disease virus type Asia1 VP1 G-H loop: effect on viral replication and neutralization phenotype. , 2012, The Journal of general virology.
[5] Li Yu,et al. Identification of a conformational epitope on the VP1 G-H Loop of type Asia1 foot-and-mouth disease virus defined by a protective monoclonal antibody. , 2011, Veterinary microbiology.
[6] B. Charleston,et al. Options for control of foot-and-mouth disease: knowledge, capability and policy , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.
[7] H. Thulke,et al. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. , 2008, Vaccine.
[8] B. Baxt,et al. Foot-and-Mouth Disease , 2004, Clinical Microbiology Reviews.
[9] A. Sanyal,et al. Antigenic characterization of foot-and-mouth disease virus serotype Asia1 field isolates using polyclonal and monoclonal antibodies. , 2003, Veterinary microbiology.
[10] D. Mackay,et al. A solid-phase competition ELISA for measuring antibody to foot-and-mouth disease virus. , 2001, Journal of virological methods.
[11] T. Macnaughton,et al. Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes , 2001, Journal of Virology.
[12] J. Casal,et al. Parvovirus-like particles as vaccine vectors. , 1999, Methods.
[13] C. Leclerc,et al. Engineering parvovirus-like particles for the induction of B-cell, CD4(+) and CTL responses. , 1999, Vaccine.
[14] M. Fernández-Fernández,et al. Development of an antigen presentation system based on plum pox potyvirus , 1998, FEBS letters.
[15] E. Domingo,et al. A Similar Pattern of Interaction for Different Antibodies with a Major Antigenic Site of Foot-and-Mouth Disease Virus: Implications for Intratypic Antigenic Variation , 1998, Journal of Virology.
[16] D. Stuart,et al. Arginine-glycine-aspartic acid-specific binding by foot-and-mouth disease viruses to the purified integrin alpha(v)beta3 in vitro , 1997, Journal of virology.
[17] H. Katinger,et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. , 1996, The Journal of general virology.
[18] E. Domingo,et al. Direct evaluation of the immunodominance of a major antigenic site of foot-and-mouth disease virus in a natural host. , 1995, Virology.
[19] P. Mason,et al. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV , 1994, Journal of virology.
[20] D. Stuart,et al. Structure of a major immunogenic site on foot-and-mouth disease virus , 1993, Nature.
[21] David Rowlands,et al. The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution , 1989, Nature.
[22] H. L. Bachrach,et al. A plaque assay for foot-and-mouth disease virus and kinetics of virus reproduction. , 1957, Virology.
[23] Md. Rejwanul Hossain,et al. Advances and Applications in Bioinformatics and Chemistry Dovepress Antigenic Heterogeneity of Capsid Protein Vp1 in Foot-and-mouth Disease Virus (fmdv) Serotype Asia1 , 2022 .
[24] B. Delmas,et al. Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. , 2009, Vaccine.